Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00364923
Other study ID # PDX-008
Secondary ID 2006-002811-29
Status Completed
Phase Phase 2
First received
Last updated
Start date August 2006
Est. completion date February 24, 2009

Study information

Verified date December 2019
Source Acrotech Biopharma LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary

• Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Secondary

- Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL

- Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation


Description:

This is a Phase 2, single arm, non-randomized, open-label, multi-center study designed to evaluate the safety and effectiveness of pralatrexate when administered with vitamin B12 and folic acid supplementation to patients with relapsed or refractory PTCL.

Pralatrexate will be given over 3-5 minutes intravenously (IV), which means through a vein. If pralatrexate is tolerated well, the patient will receive IV injections of pralatrexate every week for 6 weeks, followed by 1 week without receiving pralatrexate. These 7 week cycles will be repeated depending on response and tolerability.


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date February 24, 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically/cytologically confirmed PTCL, using the Revised European American Lymphoma (REAL) World Health Organization (WHO) disease classification:

1. T/Natural Killer (T/NK) cell leukemia/lymphoma

2. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)

3. Angioimmunoblastic T cell lymphoma

4. Blastic Natural Killer (NK) lymphoma (with skin, lymph node, or visceral involvement)

5. Anaplastic large cell lymphoma, primary systemic type

6. PTCL - unspecified

7. T/NK-cell lymphoma - nasal

8. Enteropathy-type intestinal lymphoma

9. Hepatosplenic T cell lymphoma

10. Extranodal peripheral T/NK-cell lymphoma - unspecified

11. Subcutaneous panniculitis T-cell lymphoma

12. Transformed mycosis fungoides

- Documented progression of disease after at least 1 prior treatment. Patients may not have received experimental therapy as their only prior therapy. Patient has at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Patient has recovered from the toxic effects of prior therapy. Patients treated with monoclonal antibody therapy may be enrolled regardless of the time frame of the therapy if they have progression of disease.

- Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.

- = 18 years of age.

- Adequate hematological, hepatic, and renal function.

- Women of childbearing potential must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Patients who are postmenopausal for at least 1 year or are surgically sterilized do not require this test.

- Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.

- Patient has given written informed consent.

Exclusion Criteria:

- Patient has:

1. Precursor T/NK neoplasms, with the exception of blastic NK lymphoma

2. T cell prolymphocytic leukemia (T-PLL)

3. T cell large granular lymphocytic leukemia

4. Mycosis fungoides, other than transformed mycosis fungoides

5. Sézary syndrome

6. Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphomatoid papulosis

- Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease free for greater than or equal to 5 years.

- Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure Guidelines.

- Uncontrolled hypertension.

- Human immunodeficiency virus (HIV)-positive diagnosis and is receiving combination anti-retroviral therapy.

- Patient has, or history of, brain metastases or central nervous system (CNS) disease.

- Patient has undergone an allogeneic stem cell transplant.

- Patient has relapsed less than 75 days from time of an autologous stem cell transplant.

- Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to receive protocol treatment.

- Major surgery within 2 weeks of study entry.

- Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study.

- Receipt of corticosteroids within 7 days of study treatment, unless patient has been taking a continuous dose of no more than 10 mg/day of prednisone for at least 1 month.

- Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study.

- Previous exposure to pralatrexate.

Study Design


Intervention

Drug:
Pralatrexate Injection
Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.

Locations

Country Name City State
Belgium Cliniques Universitaire Saint-Luc Brussels
Belgium Cliniques Universitaires UCL Yvoir
Canada Princess Margaret Hospital Toronto Ontario
Canada British Columbia Cancer Agency Vancouver British Columbia
France CHU Henri Mondor Creteil
France CHU DIJON - Hôpital d'enfant Dijon
France CHU Nice - Hôpital de l'Archet 1 Nice
France CHU Nantes - Hôtel Dieu Paris
France CHU Saint Louis Paris
France Centre Hospitalier Lyon Sud Pierre-Benite
France CHU Robert Debré Reims
Italy Ospedale Sant'Orsola - Policlinico Sant'Orsola Bologna
United Kingdom St. Georges Hospital London
United Kingdom The Royal Marsden NHS Foundation Trust Sutton
United States Emory University Atlanta Georgia
United States Dana-Farber Cancer Institute Boston Massachusetts
United States University of Chicago Hospital Chicago Illinois
United States City of Hope National Medical Center Duarte California
United States The Cancer Center at Hackensack University Medical Center Hackensack New Jersey
United States UT MD Anderson Cancer Center Houston Texas
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States Nevada Cancer Institute Las Vegas Nevada
United States University of California at Los Angeles Los Angeles California
United States Yale University School of Medicine New Haven Connecticut
United States Tulane Cancer Center New Orleans Louisiana
United States Columbia University Medical Center New York New York
United States Memorial Sloan-Kettering Cancer Center New York New York
United States New York Presbyterian Hospital New York New York
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States University of Rochester Cancer Center Rochester New York
United States Washington University School of Medicine Saint Louis Missouri
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Acrotech Biopharma LLC

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response Rate Per Independent Central Review Patient response to treatment was determined by independent central review using International Workshop Criteria (IWC). Results present the best overall response. The initial response assessment was scheduled at week 7 (prior to Cycle 2) and then prior to every even-numbered cycle (every 14 weeks) for up to two years after first dose. Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Secondary Duration of Response Per Independent Central Review Calculated only for those pts with an objective response. Pts receiving subsequent therapy (including transplant) before progressive disease (PD) was documented were censored at date of last response assessment obtained prior to subsequent therapy, with a note indicating censoring occurrence & reason. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last evaluable assessment of response. Pts who withdrew from treatment prior to PD or initiation of subsequent therapy without withdrawing consent were followed for disease status when possible. Measured from the first day of documented response, assessed at prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose
Secondary Progression-free Survival Per Independent Central Review Patients (pts) with subsequent therapy prior to PD were censored at date of last response assessment prior to subsequent therapy. Pts who were alive without PD were censored at the date of last assessment of first dose. Pts who withdrew consent to participate in the study prior to PD were censored at the date of their last disease assessment or treatment day 1. Pts who withdrew consent from treatment prior to PD without withdrawing consent for follow-up were followed for disease status & survival. Pts who did not have response assessments after baseline were censored at treatment day 1. Calculated as the number of days from treatment day 1 to the date of disease progression or death, regardless of cause for up to 2 years after initial dose
Secondary Overall Survival Per Independent Central Review Calculated as date of death - date of enrollment +1, estimated using the product-limit estimator. Pts who had not died (no record of death) or were lost to follow-up were censored at the date of last contact. Pts who withdrew consent to participate in the study including consent to be followed, were censored on the date of withdrawal. Pts who withdrew from treatment without withdrawing consent were followed for survival status whenever possible. Assessed every 14 weeks while on treatment, and after disease progression no less frequently than every 6 months for up to 2 years after first dose.
See also
  Status Clinical Trial Phase
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT02445404 - Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL Phase 2
Completed NCT02168140 - CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Phase 1
Completed NCT01689220 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea Phase 1
Terminated NCT01644253 - Phase 1b Safety and Efficacy Study of TRU-016 Phase 1
Completed NCT01435863 - A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Phase 1
Completed NCT01427881 - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Phase 2
Terminated NCT00441025 - The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04312841 - Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Phase 2
Recruiting NCT04040491 - PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Phase 4
Terminated NCT01678443 - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT02142530 - Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Phase 1
Completed NCT02264613 - ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Completed NCT00131937 - Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Phase 2
Completed NCT00791947 - A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Phase 2
Recruiting NCT04880746 - Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study Phase 3